Brief: Nicox Outlines Plans To Progress NCX 4251 Into Phase 2b Trial

Nicox SA

08/04/2020 06:58

April 8 (Reuters) - NICOX SA  NCOX.PA :
    * OUTLINES PLANS TO PROGRESS NCX 4251 INTO PHASE 2B TRIAL
FOLLOWING POSITIVE MEETING WITH FDA
    * AGREEMENT REACHED WITH U.S. FDA FOR NCX 4251 PHASE 2B
TRIAL
DESIGNS IN BOTH ACUTE EXACERBATIONS OF BLEPHARITIS AND REDUCTION
OF SIGNS AND SYMPTOMS OF DRY EYE DISEASE.
    * NCX 4251 HAS POTENTIAL FOR DEVELOPMENT IN BLEPHARITIS AND
IN DRY
EYE DISEASE
    * BASED ON POSITIVE OUTCOME OF DANUBE CLINICAL TRIAL, WE
WILL
CONTINUE DEVELOPMENT WITH 0.1% ONCE A DAY DOSE OF NCX 4251 -
HEAD OF RESEARCH AND DEVELOPMENT

Source text for Eikon:  ID:nGNX8CbKRX 
Further company coverage:  NCOX.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7785110;))